{"organizations": [], "uuid": "7d9f77f08fbc04e539bc915ee6232b16129375fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180507.html", "section_title": "Archive News &amp; Video for Monday, 07 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novavax-says-topline-efficacy-data/brief-novavax-says-topline-efficacy-data-from-prepare-phase-3-clinical-trial-expected-in-q1-of-2019-idUSASC0A00Y", "country": "US", "domain_rank": 408, "title": "Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.16, "site_type": "news", "published": "2018-05-07T19:14:00.000+03:00", "replies_count": 0, "uuid": "7d9f77f08fbc04e539bc915ee6232b16129375fc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novavax-says-topline-efficacy-data/brief-novavax-says-topline-efficacy-data-from-prepare-phase-3-clinical-trial-expected-in-q1-of-2019-idUSASC0A00Y", "ord_in_thread": 0, "title": "Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "novavax says topline efficacy data from prepare phase", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "novavax inc", "sentiment": "negative"}, {"name": "novavax", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 7 (Reuters) - Novavax Inc:\n* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE\n* NOVAVAX INC - TOPLINE EFFICACY DATA FROM PREPARE PHASE 3 CLINICAL TRIAL EXPECTED IN Q1 OF 2019 Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-07T19:14:00.000+03:00", "crawled": "2018-05-08T16:52:15.016+03:00", "highlightTitle": ""}